Episode

Episode 509: ASCO 2026 Review

Podcast: The Uromigos
Published: Jun 8, 2026
Duration seconds: 3312
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-509-ASCO-2026-Review-e3kfc9g
Audio: https://anchor.fm/s/13347ea8/podcast/play/121138928/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-7%2F425687559-44100-2-9effe48080a3c.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-509-asco-2026-review
Markdown: /podcast/the-uromigos-1214845/episode-509-asco-2026-review.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-509-asco-2026-review/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-509-asco-2026-review.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.